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Chronic obstructive pulmonary disease (COPD) is 
one of the most common causes of morbidity and 
mortality in South Africa (SA).[1-3] While smoking 
remains the most common risk factor for the 
development of COPD locally, long-term biomass 
fuel exposure, tuberculosis and HIV also contribute significantly 
to the disease burden.[4] In addition, poverty has been shown to be 
associated with an increased burden of COPD.[5] Pharmacotherapy 
and guidance on smoking cessation continue to form the backbone 
of management guidelines for COPD in SA.[1,6]
In advanced emphysema, therapeutic options are limited. Surgical 
lung volume reduction is known to improve functional status and 
mortality, but only in the subgroup of patients with predominant 
upper-lobe emphysema and low exercise capacity, and at the cost of 
high morbidity.[7] Endoscopic lung volume reduction (ELVR) refers 
to bronchoscopically facilitating volume loss to improve pulmonary 
mechanics and compliance,[8,9] and is now increasingly being used 
internationally for the treatment of advanced emphysema. The aim 
of ELVR is to obtain the same functional advantages as surgical lung 
volume reduction, with reduced risks and costs. These techniques 
aim to achieve regional reductions in lung volume,[8] thereby 
decreasing dynamic hyperinflation, with resultant improvement in 
diaphragm and chest wall mechanics. In addition, endobronchial 
coils in particular re-tension the airway network and in so doing 
mechanically increase elastic recoil in the emphysematous lungs, 
tethering open airways and thereby preventing airway collapse.[10]
There is a growing body of evidence that certain patients with 
advanced emphysema benefit from ELVR, provided that a systematic 
approach is followed and selection criteria are met. In addition to 
endobronchial valves, endobronchial coils for ELVR are now available 
in SA. The high cost of these interventions underscores the need for 
careful patient selection to best identify those who may or may not 
benefit from ELVR-related procedures.
The Assembly on Interventional Pulmonology of the South African 
Thoracic Society appointed a committee comprising both local and 
international experts to review the evidence and provide advice on 
the use of ELVR in SA based on published evidence, expert opinion 
and local access to the devices used for ELVR. The aim is to provide 
SA pulmonologists with an overview of the efficacy of the various 
techniques and evidence for their use, and to suggest an evidence-
based approach for the appropriate local use of these devices.
1.  Modalities and devices currently 
available in SA
1.1  Unidirectional endobronchial and  
intrabronchial valves
Unidirectional valves block entrance of air during inspiration, but 
permit exhalation of air and secretions, causing partial or complete 
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lobar collapse. The valves are self-expanding 
devices that are implanted via a catheter 
introduced through the working channel 
of a flexible bronchoscope.[8] Currently, 
Zephyr endobronchial valves (Pulmonx 
Inc., USA) and IBV intrabronchial valves 
(Olympus Respiratory America, USA) are 
commercially available in SA.
Zephyr valves (Fig. 1) are made of a 
nitinol (nickel titanium) mesh covered 
by silicone and contain a double silicone 
membrane that opens during expiration 
and closes during inspiration. They are 
available in two sizes, one for segmental 
(4.0 - 9.0 mm) and one for lobar bronchi 
(5.5 - 8.5 mm).[8] IBV valves (Fig. 2) are 
umbrella-shaped devices made of a nitinol 
mesh covered by a polyurethane membrane, 
and available in four different sizes (5, 6, 7 
and 9 mm).
Two major caveats for the use of valves 
and other bronchial blocking devices are 
the presence of either a homogeneous 
distribution of emphysema or significant 
collateral ventilation.[8] The degree of 
heterogeneity can be judged either by visual 
inspection of a high-resolution chest compu-
ted tomography (HRCT) scan or with 
specifically designed software. Heterogeneous 
emphysema is denoted by a >25% difference 
in emphysema score between ipsilateral upper 
and lower lobes, measured at a threshold of 
<−950  Houns field units.[11] In the absence 
of heterogeneous emphysema, bronchial 
blocking devices are unlikely to be successful.
Similarly, endobronchial blocking devi-
ces are unlikely to be beneficial in the 
presence of significant interlobar collateral 
ventilation. Such collateral ventilation 
prevents atelectasis and thereby subverts the 
deflating effect of the devices. The presence 
of incomplete fissures, seen on an HRCT 
scan, is considered a proxy for physiological 
interlobar collateral ventilation. Recent 
evidence suggests that if the fissures are 
<75% intact, further evaluation should 
not be performed as collateral ventilation 
is always present, whereas with >90% 
complete fissures, collateral ventilation 
is practically never present. The Chartis 
system is an endobronchial catheter system 
(Chartis Pulmonary Assessment System; 
Pulmonx Inc.) used to directly measure 
the percentage of interlobar collateral 
ventilation in patients with between 75% 
and 90% fissural integrity.[12] The system 
is made up of a balloon catheter that is 
connected to a console and inserted into an 
airway via a bronchoscope. Once inflated 
it occludes the bronchus, preventing direct 
outflow of inspired air. A near-constant rate 
of expiratory airflow during the assessment 
is observed in cases with collateral 
ventilation, whereas a steady reduction in 
flow is observed in the absence of collateral 
ventilation.[12]
The current evidence for the use of 
endobronchial and intrabronchial valves 
is summarised in Table 1. Although nume-
rous observational and randomised trials 
showed statistical benefits in respect of 
practically all functional parameters, 
minimal clinically important differences 
(MICDs) were significantly more likely 
to be observed in patients with advanced 
heterogeneous emphysema and no collateral 
ventilation and in those in whom unilateral 
valve placement achieved complete lobar 
collapse.[13-19] The most common reported 
adverse events were pneumothoraces 
(5 - 10%), mild haemoptysis (2 - 6%) and 
exacerbations of underlying COPD (8 - 
40%).
The recently completed STELVIO trial 
provided the strongest evidence for use 
of valves in patients without collateral 
ventilation.[19] Dutch investigators random-
ised 68 patients with severe heterogeneous 
emphysema on HRCT with visual esti-
mation of complete or near-complete 
fissures to endobronchial Zephyr valve 
treatment (n=34) or standard medical care 
(n=34). The primary outcome measures 
were change in spirometric measures and 
6-minute walking distance (6MWD) at 6 
months. Clinical relevance was assessed 
relative to MICDs. At 6 months, the 
MICDs were attained in all parameters in 
the treated group compared with controls 
(p<0.001 for all endpoints).
1.2 Coils
Coils (RePneu; BTG Inc., USA) are nitinol 
devices (Fig. 3) designed to be straightened 
for deployment into a subsegmental 
airway, and thereafter to resume their 
preformed shape.[10] This conformational 
shape change after deployment results in 
parenchymal retraction with volume loss, 
while maintaining airway patency.[10] The 
device is currently available in three lengths 
(100, 125 and 150 mm) to accommodate 
different-sized airways. The coils are 
implanted via a flexible bronchoscope 
under general anaesthesia or conscious 
sedation and fluoroscopic guidance using a 
proprietary delivery system.
Current evidence (Table 2) suggests that 
candidates with both heterogeneous and 
homogeneous emphysema can experience 
clinically significant benefit from ELVR 
using coils.[10,20-23] This benefit is obtained 
regardless of the presence of collateral 
ventilation, or complete lobar collapse 
post insertion, but requires that no more 
than 75% of the total lung parenchyma is 
destroyed by emphysema prior to inser-
tion.[11,22] Approximately 75 - 80% of patients 
will experience MICDs in lung function 
and quality of life, while mild haemoptysis 
of <5 mL (50 - 75%), exacerbations of 
COPD (5 - 12%), mild chest discomfort 
(15 - 50%) and infrequent pneumothoraces 
(3%) are the described adverse events.[11,22] 
A recent report on the 3-year follow-up 
data of 38 patients who underwent ELVR 
using coils suggested that the coil treatment 
was safe; no late pneumothoraces, coil 
migrations or unexpected adverse events 
occurred.[23] Although clinical benefit 
declined gradually over time, at 3 years after 
treatment approximately 50% of patients 
maintained improvements in 6MWD and 
subjective dyspnoea, as well as quality of 
life scores.
Fig. 2. Intrabronchial (IBV) valves of varying 
diameters.
Fig. 1. Endobronchial (Zephyr) valves of varying 
diameters for lobar or segmental occlusion.
Fig. 3. Endobronchial (RePneu) coils of varying 
lengths.
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Table 1. Summary of key clinical studies that evaluated the safety and efficacy of ELVR with valves
Study details Design 
Primary efficacy 
measures Major outcomes
Major adverse 
events Comments
Snell et al.,[13] 2003
Number enrolled: 10
Case series: bilateral ELVR 
(feasibility study)
NA No major change in 
radiological findings, 
lung function or 
6MWD; DLCO 
improved from mean 
(SD) 7.47 (2.0) to 
8.26 (2.6) mL/min/
mmHg (p=0.04)
No major 
complications (at 
30 days). Minor 
complications 
included 
exacerbation of 
COPD (n=3), 
asymptomatic 
pneumothorax 
(n=1) and 
pneumonia (n=1)
Showed that ELVR with 
valves was feasible and 
safe, but that further 
studies were needed 
to explore patient 
characteristics that 
determine symptomatic 
efficacy
Toma et al.,[14] 2003
Number enrolled: 8
Case series: unilateral 
ELVR (feasibility study)
NA Median FEV1 
increased from 0.79 to 
1.06 L (p=0.028) and 
median DLCO from 
3.05 to 3.92 mL/min/
mmHg (p=0.017)
Pneumothorax 
(n=2)
Acceptable short-term 
safety
VENT (USA) trial 
(Sciurba et al.[15]), 
2010
Number enrolled: 321 
RCT (2:1): unilateral ELVR 
v. standard medical care
Changes in FEV1 
and 6MWD at 6 
months
FEV1 1.9% higher 
(p=0.007) and 
6MWD 19.1 m 
more (p=0.02) in 
treated group; SGRQ 
decreased by 3.4 
(p=0.04)
COPD exacerbation 
requiring 
hospitalisation (7.9% 
v. 1.1%) (p=0.03) 
and haemoptysis 
(6.1% v. 0% (p=0.01). 
Pneumonia in target 
lobe (4.2%)
Greater radiographic 
evidence of emphysema 
heterogeneity and 
fissure completeness 
was associated with an 
enhanced response to 
treatment
VENT (Europe) trial 
(Herth et al.[16]), 2012
Number enrolled: 60
RCT (2:1): unilateral ELVR 
v. standard medical care
Changes in FEV1, 
cycle ergometry 
and SGRQ at 6 
months
Mean change in 
FEV1 7.0% v. 0.5% 
(p=0.067); cycle 
ergometry 2W v. 
3W (p=0.04); SGRQ 
–5 v. 0.3 points 
(p=0.047)
Pneumothorax 
(n=5). No 
difference in COPD 
exacerbation rates
Superior clinical 
results with computed 
tomography suggestive 
of complete fissures and 
with successful lobar 
occlusion
Ninane et al.,[17] 2012
Number enrolled: 73
Sham-controlled study 
(1:1): bilateral ELVR 
without lobar collapse
≥4-point 
improvement in 
SGRQ
24% responders in 
treated group v. 0% 
in control group 
(p=0.002)
COPD exacerbation 
13% v. 9% (p=0.595)
Not effective in 
majority; major 
finding was that 
complications are due 
to bronchoscopy itself 
rather than device 
Eberhardt et al.,[18] 
2012
Number enrolled: 22
RCT (1:1): bilateral 
(incomplete occlusion ) 
v. unilateral (for total 
occlusion) treatment 
FEV1, 6MWD, 
SGRQ
FEV1 improved in 
unilaterally treated 
group but not in the 
other group (21.4% 
v. 0.03%) (p=0.002)
Respiratory 
failure (n=2), 
pneumothorax 
(n=1)
Unilateral valve 
placement with 
complete occlusion 
superior to bilateral 
partial occlusion
STELVIO trial 
(Klooster et al.[19]), 
2015
Number randomised: 
68
RCT (1:1): unilateral ELVR 
(collateral ventilation 
excluded) v. standard 
medical care
FEV1, FVC, RV 
and 6MWD at 6 
months
FEV1 22.7%,  
FVC 442 mL,  
RV –831 mL,  
6MWD 106 m and 
SGRQ –14.7 points 
superior in treated 
group (all p<0.001) 
Pneumothorax 
17.6% 
Best evidence that 
ELVR with valves in 
the absence of collateral 
ventilation results 
in statistically and 
clinically significant 
improvements in 
pulmonary function, 
exercise capacity and 
quality of life
RCT = randomised controlled trial; NA = not applicable; FEV1 = forced expiratory volume in 1 second; 6MWD = 6-minute walking distance; SGRQ = St George’s respiratory questionnaire;  W=watt; FVC = forced vital capacity; RV = residual volume; DLCO = carbon monoxide diffusing capacity; SD = standard deviation.
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2. Modalities not available in SA
2.1 Bronchial spigots 
Watanabe Spigots (Novatech, France) have been used successfully in the 
manage ment of pulmonary fistula and persistent pneumothorax with 
continuous air leakage.[24] Despite many reports describing successful 
treatment of persistent air leaks using endobronchial Watanabe Spigots, 
evidence for their use in the context of ELVR for emphysema is lacking.
2.2 Sealants
The AeriSeal system (Aeris Therapeutics Biological, Pulmonx Inc.) 
uses synthetic polymeric foam to obtain atelectasis. A recent multi-
centre randomised controlled trial, terminated early for financial 
reasons, confirmed significantly improvements from baseline in lung 
function, dyspnoea and quality of life when compared with controls 
at 3 months, but the fact that 44% of treated patients experienced 
adverse events requiring hospitalisation (including two deaths) raised 
some safety concerns.[25]
2.3 Vapour
Bronchoscopic thermal vapour ablation (InterVapor; Uptake Medical, 
USA) uses high-temperature water vapour delivered into the target 
lung segments through a catheter with precise amount of energy, 
thereby inducing thermal damage resulting in permanent airway 
fibrosis.[8] Although one potential advantage of this technology is 
that it is not influenced by interlobar collateral ventilation, it has 
been shown to have a relatively modest effect on lung function.[26,27] 
Adverse events, particularly COPD exacerbations, are frequently 
observed.[28]
2.4 Airway bypass
The technique of airway bypass is based on the creation of extra-
anatomical passages between the hyperinflated lung parenchyma 
and larger airways.[8] Evidence suggests that although some short-
term benefit may be achieved in patients with severe hyperinflation, 
pulmonary function appears to return to baseline within 3 months.[29-31]
Table 2. Summary of key clinical studies that evaluated the safety and efficacy of ELVR with coils
Study details Design Efficacy measures Outcome Major adverse events Comments
Herth et al.,[10] 2010
Number enrolled: 11
Case series 
(feasibility study)
NA NA COPD exacerbations 
(mild), no 
pneumothorax 
ELVR with coils was 
deemed safe and 
feasible
Slebos et al,[20] 2012
Number enrolled: 16
Prospective cohort 
pilot study
SGRQ, FEV1, FVC, 
RV, 6MWD
SGRQ improved 
by 14.9 points (in 
11 patients by >4 
points), FEV1 by 
14.9%, FVC by 
13.4%, RV by 11.4% 
and 6MWT by  
84.4 m (all p<0.005)
Pneumothorax (n=1), 
pneumonia (n=2), 
COPD exacerbation 
(n=6), chest pain 
(n=4), mild (<5 mL) 
haemoptysis (n=21)
First study to 
show signiﬁcant 
improvements in 
pulmonary function, 
exercise capacity, 
and quality of life
RESET trial (Shah et al.[21]), 
2013
Number enrolled: 47 
RCT (1:1): bilateral 
ELVR v. standard 
medical care
SGRQ −8.63 (p=0.04) COPD exacerbation 
(4%)
Evidence of improved 
quality of life
Deslee et al.,[11] 2014
Number enrolled: 60
Prospective 
multicentre cohort 
trial
SGRQ, pulmonary 
function testing, 
mMRC and 6MWD 
up to 12 months 
ΔSGRQ −11.1 
points, Δ6MWD 
+51.4 m, ΔFEV1 
+0.11 L, and ΔRV 
−0.71 (all p<0.01) 
COPD exacerbation 
(6.1%), pneumonia 
(5.2%), pneumothorax 
(3.5%), haemoptysis 
(0.9%)
Significant 
responses for both 
heterogeneous 
and homogeneous 
emphysema
Klooster et al.,[22] 2014
Number enrolled: 10
Prospective single-
centre cohort trial
Change in 6MWD 
at 6 months
6MWD improved 
from 289 to 350 
m (p=0.005), FVC 
from 2.17 to 2.55 
L (p=0.047), RV 
from 5.04 to 4.44 
L (p=0.007) and 
SGRQ from 63 to 
48 points (p=0.028)
Pneumothorax 
(n=1), slight (<5 mL) 
haemoptysis (n=5), 
chest discomfort (n=6), 
COPD exacerbation 
(n=5)
The benefit of LVR 
coil treatment is not 
limited to patients 
with heterogeneous 
emphysema
Hartman et al.,[23] 2015
Number enrolled: 38
Prospective single-
centre cohort trial
mMRC, pulmonary 
function testing and 
6MWD at 5 years
Significant 
improvement 
in mMRC score 
remained, with 
40% of the patients 
reaching the 
6MWD MICD and 
59% the SGRQ 
MICD
No device-related 
complications 
Best long-term data 
on safety of coils 
NA = not applicable; SGRQ = St George’s respiratory questionnaire; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; RV = residual volume;  6MWD = 6-minute walking distance; mMRC = modified Medical Research Council dyspnoea score; Δ = change.
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3.  Evaluation of 
candidates for 
potential lung volume 
reduction
The initial screening of potential candidates 
with stable disease should ideally be 
performed by pulmonologists, and should 
include an assessment of severity of dyspnoea, 
functional impairment, past thoracic surgery, 
comorbidities and smoking status.
Routine special investigations should include 
an HRCT scan (to estimate heterogeneity, 
integrity of fissures and degree of tissue 
destruction, and to exclude occult malignancy), 
full pulmonary function testing (including 
measurements of forced expiratory volume 
in 1 second, forced vital capacity, residual 
volume (RV), RV/total lung capacity (TLC), 
TLC, carbon monoxide diffusing capacity 
and 6MWD), arterial blood gas measurement 
and echocardiography (to exclude pulmonary 
artery pressures >50 mmHg).
The general indications for and contra-
indications to valves and coils are summar-
ised in Table 3. ELVR should not be offered 
to active smokers, patients with pulmonary 
hypertension, unstable cardiac patho logy, 
active respiratory infections, a very poor 
exercise tolerance or no clear evidence of 
hyperinflation, or to patients on any type 
of long-term antiplatelet or anticoagulant 
therapy that cannot be stopped 7 days before 
the procedure.
Appropriate or borderline candidates should 
be referred to a centre with the capacity to 
evaluate and treat them and follow them 
up, including managing complications and 
removal of devices if required. These centres 
should individualise the interventions on the 
basis of disease phenotype (e.g. heterogeneous 
v. homogeneous disease), degree of tissue 
destruction, the presence of collateral 
ventilation and pulmonary impairment.
4.  Suggested approach to 
ELVR in SA
There is currently no official guideline from 
any of the major thoracic societies and no 
head-to-head evidence comparing the various 
techniques and devices. The Assembly 
on Interventional Pulmonology of the SA 
Thoracic Society has therefore based the 
approach summarised in Fig. 4 on the available 
published evidence, availability of the devices 
in SA and international expert opinion.
The degree of severity of emphysema, the 
degree of tissue destruction, heterogeneity 
of the disease and the presence of collateral 
ventilation are all important factors in the 
final selection process.[8] The algorithm 
presented in Fig. 4 should not be viewed as a 
rigid guideline, and the clinician should still 
use discretion, especially in those patients 
who may potentially benefit from either coils 
or valves. For example, patients with 25 - 75% 
tissue destruction and no collateral ventilation 
may also benefit from valves, although the 
reported response rates and improvements 
in functional status and pulmonary function 
tests seem to be greater with coils.[7-9,16,19]
It is recommended that all ELVR 
procedures should be performed in the 
context of a local and/or international 
registry. The Assembly on Interventional 
Pulmonology of the SA Thoracic Society is 
willing to assist potential centres wanting 
to establish an ELVR service in terms of 
training and accreditation.
5. Conclusions
Appropriate candidates with marked hyper-
inflation and relatively preserved lung 
parenchyma are more likely to benefit from 
ELVR with bilateral coils, irrespective of 
the collateral ventilation and heterogeneity 
of the disease. In contrast, patients with 
heterogeneous disease and no collateral 
ventilation are more likely to benefit from 
unilateral ELVR with valves, aiming to achieve 
complete lobar collapse. A well-structured 
evidence-based approach to ELVR, including 
initial screening and subsequent referral to 
a specialised centre, is important to avoid 
inappropriate use of devices, which may be 
both wasteful and harmful.
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•   40 - 75 years old
•   Dyspnoea despite maximal
    medical therapy &
    pulmonary rehabilitation
•   FEV1 15 ‐ 45%
•   Hyperination (TLC >100%
    & RV >150 - 175%)
•   PaCO2 <6.7 kPa
•   PaO2 >6 kPa (ambient air)
•   6MWD ≥140 m
General inclusion criteria General exclusion criteria
•    Current smoking (last 6 months)
•    DLco <20%
•    Giant bullae (>1/3 of hemithorax)
•    α1-antitrypsin deciency
•    Previous thoracotomy, pleurodesis or chest wall deformity
•    Severe pulmonary hypertension (>50 mmHg)
•    Active infection or unstable cardiac conditions
•    Signicant pleural or interstitial changes on HRCT
•    Antiplatelet/anticoagulant therapy that cannot be stopped
Initial review of patient with stable emphysema (performed by pulmonologist)
Modality-specic review by specialist centre
Parenchymal destruction on HRCT
LVR not an option
Coils Valves Consider LVRS
Collateral ventilation
(HRCT reconstruction or Chartis)
Negative
(with low baseline perfusion)
Positive
(with low excercise capacity)
Heterogeneous disease Homogeneous disease
≤75% >75%
*
Fig. 4. Suggested approach to ELVR in SA. (*Patients with 25 - 75% of tissue destruction and no collateral circulation may also benefit from valves, although the 
reported response rates and improvements in functional status and pulmonary function test seem to favour ELVR with coils. LVR = lung volume reduction; LVRS = 
lung volume reduction surgery; FEV1 = forced expiratory volume in 1 second; TLC = total lung capacity; RV = residual volume; PaCO2 = partial pressure of carbon 
dioxide; PaO2 = partial pressure of oxygen; 6MWD = 6-minute walking distance; DLCO = carbon monoxide diffusing capacity.)
